The high frequency of PI3K activation, coupled with its essential roles in cell growth, proliferation, and survival, is consistent with preclinical and clinical activity of the p110α-selective PI3K inhibitor alpelisib in HR+ breast cancer. This evidence concerns the gene PIK3CA and breast carcinoma.